BSEM

BioStem Technologies, Inc. BSEM

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$7.90M

Quarter to Jun 30

Net income

$-8.97M

Quarter to Jun 30

Operating margin

-106.3%

Quarter to Jun 30

Top Institutional Holders

as of Q3 2026
$1.7K total
WOLFF WIESE MAGANA LLC
$1.1K--
BIRCHBROOK, INC.
$618--
See all 2 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2027
EDGAR

Net Income

Q1 2027
EDGAR

EPS (Diluted)

Q1 2027
EDGAR

Operating Margin

Q1 2027
EDGAR

Debt/Equity

Q1 2027
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BSEM

Earnings Per Share

13fpro.ai/company/BSEM

Loading ratio trend…

BSEM key financials by period

Reported revenue, net income and operating margin by fiscal year, from BioStem Technologies, Inc.'s annual filings on SEC EDGAR.

BioStem Technologies, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$47.5M$-6.6M-1.5%
FY 2024$69.7M$31.0M44.7%
Source: BSEM filings on SEC EDGAR →

BSEM insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About BioStem Technologies, Inc. (BSEM): stock profile, AI score and financials

BioStem Technologies, Inc. (BSEM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BSEM is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q1 2027), BioStem Technologies, Inc. reports quarterly revenue of $7.9M, net income of $-9.0M, an operating margin of -106.3%. BSEM trades on the Nasdaq exchange and files with the SEC under CIK 1658678. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BSEM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioStem Technologies, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1658678 →